Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 10/20 | 0.37 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027778 | 0.89 | AURKB (0.42) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3044950 | 0.85 | AURKB (0.42) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3038656 | 0.83 | AURKB (0.42) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3044203 | 0.81 | IGF1R (0.43) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3035031 | 0.79 | SRC (0.51) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL13221256 | 0.78 | AURKB (0.53) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3042680 | 0.77 | AURKB (0.55) | GSK3BAURKBSRCKDRMET | |
| SCHEMBL13221255 | 0.77 | AURKB (0.52) | CCNE1CDK2GSK3BAURKBSRC | |
| SCHEMBL3037063 | 0.76 | AURKB (0.51) | GSK3BAURKBSRCIGF1RAURKA | |
| SCHEMBL13221238 | 0.76 | AURKB (0.51) | CDK2GSK3BAURKBSRCIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | claimed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CCNE1 639/4885CDK2 74/4885GSK3B 200/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CCNE1 639/4885CDK2 74/4885GSK3B 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.